Merot J, Charpentier F, Poirier J M, Coutris G, Weissenburger J
Laboratoire de Physiopathologie & Pharmacologie Cellulaires & Moléculaires, INSERM CJF 96-01, Nantes, France.
Cardiovasc Res. 1999 Nov;44(2):303-14. doi: 10.1016/s0008-6363(99)00232-1.
The present study was designed to examine the effects of chronic amiodarone on the different ventricular cell subtypes in situ and to evaluate its interactions with sotalol.
Three groups of dogs were studied. Group I (n = 8) received no treatment. Group II (n = 7) and group III (n = 8) received, respectively, 100 and 200 mg amiodarone orally twice a day for 6 weeks to 8 months. In vivo studies were performed under halothane anesthesia 14 h after the last administration of amiodarone. Three leads ECG, femoral blood pressure and left ventricular intramural monophasic action potentials (MAP) were continuously recorded. Bradycardia was obtained by clamping the sinus node and beta-blockade and the heart was driven by atrial pacing. Three weeks before the in vivo experiments, the cellular electrophysiologic properties of right ventricular tissues obtained by cardiac biopsy in six treated and six control dogs were studied with standard microelectrodes.
Amiodarone produced a dose-dependent decrease in plasma levels of triiodothyronine (T3; 5.9 +/- 0.4 pM in control dogs, 3.1 +/- 0.2 pM in group III, P < 0.001) without affecting thyroxine (T4). Under anesthesia, the QT interval was 14% larger in group III compared to group I at a paced cycle length (PCL) of 1500 ms (P < 0.05). This is consistent with the 10% increase in endocardial MAP duration in group III at the same PCL (P < 0.05). There was no significant increase in transmural dispersion of MAP duration. In group I, sotalol induced a significant reverse use-dependent increase in MAP duration. This effect was reduced in group II and completely suppressed in group III. Amiodarone prevented the sotalol-induced increase in transmural dispersion of ventricular repolarization which was 69 +/- 12 ms in untreated dogs, 41 +/- 8 ms in group II (P < 0.05) and 34 +/- 8 ms (P < 0.05) in group III at PCL = 1500 ms. Amiodarone also prevented the sotalol-induced ventricular tachyarrhythmias. In vitro, the action potential duration was longer in amiodarone-treated dogs that in control ones (208 +/- 5 ms versus 188 +/- 9 ms at PCL = 1000 ms, P < 0.05). The sotalol-induced prolongation of repolarization was reduced in amiodarone-treated dogs.
Chronic treatment of dogs with amiodarone induced a moderate prolongation of the QT interval and MAP duration without affecting transmural dispersion of repolarization and inhibited the effects of acute sotalol, including the prolongation of repolarization, the increase in transmural dispersion of repolarization and the induction of arrhythmias.
本研究旨在检测慢性胺碘酮对不同心室细胞亚型的原位影响,并评估其与索他洛尔的相互作用。
对三组犬进行研究。第一组(n = 8)未接受治疗。第二组(n = 7)和第三组(n = 8)分别每天口服100和200 mg胺碘酮,持续6周~8个月。在最后一次给予胺碘酮14小时后,在氟烷麻醉下进行体内研究。连续记录三导联心电图、股动脉血压和左心室内膜单相动作电位(MAP)。通过钳夹窦房结和β受体阻滞诱导心动过缓,并用心房起搏驱动心脏。在体内实验前三周,用标准微电极研究了六只治疗犬和六只对照犬经心脏活检获得的右心室组织的细胞电生理特性。
胺碘酮使血浆三碘甲状腺原氨酸(T3)水平呈剂量依赖性降低(对照犬为5.9±0.4 pM,第三组为3.1±0.2 pM,P < 0.001),而不影响甲状腺素(T4)。在麻醉状态下,在1500 ms的起搏周期长度(PCL)时,第三组的QT间期比第一组大14%(P < 0.05)。这与第三组在相同PCL时心内膜MAP持续时间增加10%一致(P < 0.05)。MAP持续时间的跨壁离散度没有显著增加。在第一组中,索他洛尔诱导MAP持续时间出现显著的反向使用依赖性增加。在第二组中这种效应减弱,在第三组中完全被抑制。胺碘酮可防止索他洛尔诱导的心室复极跨壁离散度增加,在未治疗的犬中为69±12 ms,在第二组中为41±8 ms(P < 0.05),在第三组中为34±8 ms(P < 0.05),PCL = 1500 ms。胺碘酮还可防止索他洛尔诱导的室性快速心律失常。在体外,胺碘酮治疗的犬的动作电位持续时间比对照犬长(在PCL = 1000 ms时为208±5 ms对188±9 ms,P < 0.05)。在胺碘酮治疗的犬中,索他洛尔诱导的复极延长减少。
用胺碘酮对犬进行慢性治疗可使QT间期和MAP持续时间适度延长,而不影响复极的跨壁离散度,并抑制急性索他洛尔的作用,包括复极延长、复极跨壁离散度增加和心律失常的诱导。